Company / R&D Expense
Neurogene Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$60.9M
FY2025
5-year range
$28.4M / $60.9M
FY2021-FY2025
Trend
+37.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $28M to $61M over the past 7 years.
Based on SEC 10-K filings.
$61M in FY2025.
Improved from $28M to $61M over the past 7 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d expense increased 37.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.24 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $60.9M | +37.2% |
| FY2024 | $44.4M | - |
| FY2019 | - | - |
| FY2018 | $28.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026